Asset Details
Do you wish to reserve the book?
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
Do you wish to request the book?
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
2018
Overview
Background
Previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer (EC), while the results have been inconsistent. This systematic review and meta-analysis aimed to investigate the association between metformin use and risk and prognosis of patients with EC.
Methods
PubMed, Embase, and the Cochrane Library databases were searched for observational studies evaluating the effect of metformin on EC prevention or treatment. The odds ratio (OR) was used for analyzing risks, and the hazard ratio (HR) was used for analyzing survival outcomes. A random-effects model was used for data analysis.
Results
Seven studies reported data on EC risk. The pooled results suggested that metformin was not significantly associated with a lower risk of EC [OR = 1.05, 95% confidence interval (CI) 0.82–1.35, P = 0.70]. For patients with diabetes, metformin showed no advantage in reducing the EC risk compared with other interventions (OR = 0.99, 95% CI 0.78–1.26, P = 0.95). Further, seven studies were included for survival analysis. The pooled data showed that metformin could significantly improve the overall survival of patients with EC (HR = 0.61, 95% CI 0.48–0.77,
P
< 0.05) and reduce the risk of EC recurrence (OR = 0.50, 95% CI 0.28–0.92,
P
< 0.05) Finally, we noted metformin was associated with significantly improving the overall survival of EC patients among diabetes (HR = 0.47; 95%CI 0.33–0.67,
P
< 0.05).
Conclusions
This meta-analysis did not prove that metformin was beneficial for preventing EC. However, metformin could prolong the overall survival of patients with EC and reduce their risk of cancer relapse.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Complications and side effects
/ Endometrial Neoplasms - mortality
/ Endometrial Neoplasms - pathology
/ Endometrial Neoplasms - prevention & control
/ Experimental therapeutics and drug development
/ Female
/ Health Promotion and Disease Prevention
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Metformin - administration & dosage
/ Oncology
/ Risk
